Odyssean LLC Buys 87,308 Shares of IDEAYA Biosciences, Inc. $IDYA

Odyssean LLC raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 571.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 102,582 shares of the company's stock after buying an additional 87,308 shares during the quarter. IDEAYA Biosciences comprises approximately 0.6% of Odyssean LLC's investment portfolio, making the stock its 3rd biggest holding. Odyssean LLC owned 0.12% of IDEAYA Biosciences worth $3,823,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in IDEAYA Biosciences during the second quarter worth about $331,452,000. Jupiter Topco LLC bought a new stake in IDEAYA Biosciences in the second quarter valued at approximately $319,728,000. GSK plc acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $46,093,000. State Street Corp lifted its position in shares of IDEAYA Biosciences by 27.6% in the fourth quarter. State Street Corp now owns 4,134,641 shares of the company's stock valued at $142,935,000 after buying an additional 893,707 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of IDEAYA Biosciences by 11.8% during the 4th quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company's stock worth $248,344,000 after acquiring an additional 758,117 shares during the period. Institutional investors and hedge funds own 98.29% of the company's stock.

Analyst Upgrades and Downgrades

IDYA has been the topic of a number of recent analyst reports. Citigroup reissued a "market outperform" rating on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Wall Street Zen downgraded IDEAYA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Royal Bank Of Canada reduced their price objective on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an "outperform" rating for the company in a research report on Tuesday, July 7th. Wedbush upped their price objective on shares of IDEAYA Biosciences from $58.00 to $60.00 and gave the company an "outperform" rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of IDEAYA Biosciences in a research report on Friday, July 17th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, IDEAYA Biosciences currently has an average rating of "Moderate Buy" and a consensus target price of $50.12.

Insider Transactions at IDEAYA Biosciences

In other IDEAYA Biosciences news, CAO Briseno Andres Ruiz sold 9,550 shares of the company's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the transaction, the chief accounting officer directly owned 26,466 shares of the company's stock, valued at $1,058,904.66. This represents a 26.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.70% of the stock is owned by company insiders.

IDEAYA Biosciences Stock Up 6.1%

Shares of NASDAQ:IDYA opened at $42.48 on Wednesday. IDEAYA Biosciences, Inc. has a 12-month low of $23.23 and a 12-month high of $42.68. The stock has a market cap of $3.73 billion, a PE ratio of -21.90 and a beta of -0.10. The business has a 50 day moving average of $36.57 and a 200-day moving average of $32.98.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.06) by ($0.16). The firm had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.IDEAYA Biosciences's revenue for the quarter was up 8800.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.88) EPS. Equities research analysts expect that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source